Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- Conditions
- Metastatic SarcomaRecurrent SarcomaResectable Sarcoma
- Interventions
- Device: Drug Delivery MicrodeviceProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04199026
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
- Conditions
- Hereditary Hemorrhagic TelangiectasiaEpistaxis
- Interventions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Cure HHT
- Target Recruit Count
- 30
- Registration Number
- NCT03850730
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
- Conditions
- Hereditary Hemorrhagic TelangiectasiaNosebleedHHTEpistaxisAnemia
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Cure HHT
- Target Recruit Count
- 70
- Registration Number
- NCT03850964
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸University of Colorado, Denver, Colorado, United States
🇺🇸Augusta University, Augusta, Georgia, United States
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 46
- Registration Number
- NCT03798106
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib
- Conditions
- Soft Tissue Sarcoma Adult
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 11
- Registration Number
- NCT03735758
- Locations
- 🇩🇪
Vivantes Klinikum Spandau, Berlin, Germany
🇩🇪Uniklinik Frankfurt, Frankfurt, Germany
🇩🇪Universitätsklinikum Mannheim, Mannheim, Germany
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
- Conditions
- Metastatic Soft Tissue SarcomaAdvanced Soft Tissue SarcomaLocally Advanced Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 19
- Registration Number
- NCT03660930
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
- Conditions
- Refractory Pediatric Solid TumorRelapsed Pediatric Solid Tumor
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT03628131
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Xynomic Pharmaceuticals, Inc.
- Target Recruit Count
- 413
- Registration Number
- NCT03592472
- Locations
- 🇪🇸
H.U. Virgen de la Victoria, Málaga, Spain
🇪🇸H.G.U. de Elche, Elche, Spain
🇪🇸Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
- Conditions
- Kidney Cancer
- Interventions
- Combination Product: CK2 and ATM inhibitors serine/ threonin Kinase combination
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 100
- Registration Number
- NCT03571438
- Locations
- 🇫🇷
Grenoble Alps Hospital, Grenoble, France
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
- Conditions
- Unresectable Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v7Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 5
- Registration Number
- NCT03334409
- Locations
- 🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
🇺🇸Sanford Medical Center Fargo, Fargo, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.